There are no "specific epigenetic drugs", but there are a few that are able to directly affect DNA methylation, histone modification and micro-RNAs. These therapies have to be used very individually, as they are not unified in every tumor patient with the same tumor-associated epigenetic alterations.
In Germany, the histone deacetylase inhibitor panobinostat, among others, is approved in a combination therapy for relapsed or refractory multiple myeloma. For myelodysplastic syndrome, chronic myelomonocytic leukemias and acute myeloid leukemia, the DNA methyltransferase inhibitors 5-azacytidine and decitabine (5-aza-2'-deoxycytidine) are approved.
However, considerable cytotoxic effects must be accepted here in part because the DNA methyltransferase inhibitors act relatively nonspecifically on genome-wide DNA methylation.
A considerably more important pillar in the accompanying therapy of cancer, autoimmune processes, inflammation and chronic, toxin-induced CFS, is phosphatidylcholine (not lecitin!), especially from the group of phospholipids, as well as a number of important micronutrients and vitamins, for which we can help you to draw up a possible, therapeutic "step-by-step plan".